Literature DB >> 23416851

Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.

Rainer Storb1, Boglarka Gyurkocza, Barry E Storer, David G Maloney, Mohamed L Sorror, Marco Mielcarek, Paul J Martin, Brenda M Sandmaier.   

Abstract

Most patients with hematologic malignancies have received extensive chemotherapy before hematopoietic cell transplantation (HCT), resulting in neutropenia, lymphocytopenia, and use of antibiotics. Accordingly, patients have a wide range of neutrophil counts, lymphocyte counts, and previous antibiotic use. The minimal toxicity of the current conditioning regimen allowed us to ask whether peritransplantation neutrophil or lymphocyte levels influences the risks of acute graft-versus-host disease (GVHD) or relapse. We analyzed outcomes in 459 patients age 7-75 years (median, 57 years) who received conditioning with fludarabine and low-dose total body irradiation for HLA-matched HCT. We report 2 key findings. First, low neutrophil nadirs within the first 3 weeks post-HCT had significant associations with increased risks of acute GVHD and 5-year nonrelapse mortality, but showed no association with the risk of relapse. Second, high lymphocyte counts immediately before HCT had significant associations with reduced risks of relapse and overall mortality, but no association with the risks of GVHD or nonrelapse mortality. These findings suggest that the immunologic mechanisms involved in acute GVHD might differ from those that initiate graft-versus-tumor effects.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23416851      PMCID: PMC3629007          DOI: 10.1016/j.bbmt.2013.02.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  40 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Probiotic effects on experimental graft-versus-host disease: let them eat yogurt.

Authors:  Armin Gerbitz; Michael Schultz; Andrea Wilke; Hans-Jörg Linde; Jürgen Schölmerich; Reinhard Andreesen; Ernst Holler
Journal:  Blood       Date:  2004-02-12       Impact factor: 22.113

3.  Graft-versus-tumor effect according to type of graft-versus-host disease defined by National Institutes of Health consensus criteria and associated outcomes.

Authors:  Byung-Sik Cho; Sung-Eun Lee; Hae-Hiang Song; Ju-Hyoung Lee; Seung-Ah Yahng; Ki-Seong Eom; Yoo-Jin Kim; Hee-Je Kim; Seok Lee; Chang-Ki Min; Seok-Goo Cho; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Chong-Won Park
Journal:  Biol Blood Marrow Transplant       Date:  2012-01-16       Impact factor: 5.742

4.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.

Authors:  Frédéric Baron; Michael B Maris; Brenda M Sandmaier; Barry E Storer; Mohamed Sorror; Razvan Diaconescu; Ann E Woolfrey; Thomas R Chauncey; Mary E D Flowers; Marco Mielcarek; David G Maloney; Rainer Storb
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

5.  Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial.

Authors:  D W Beelen; A Elmaagacli; K D Müller; H Hirche; U W Schaefer
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

6.  Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.

Authors:  Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

7.  The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation.

Authors:  S Thepot; J Zhou; A Perrot; M Robin; A Xhaard; R P de Latour; L Ades; P Ribaud; A D Petropoulou; R Porcher; G Socié
Journal:  Leukemia       Date:  2010-09-09       Impact factor: 11.528

8.  Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Christoph Kahl; Barry E Storer; Brenda M Sandmaier; Marco Mielcarek; Michael B Maris; Karl G Blume; Dietger Niederwieser; Thomas R Chauncey; Stephen J Forman; Edward Agura; Jose F Leis; Benedetto Bruno; Amelia Langston; Michael A Pulsipher; Peter A McSweeney; James C Wade; Elliot Epner; Finn Bo Petersen; Wolfgang A Bethge; David G Maloney; Rainer Storb
Journal:  Blood       Date:  2007-06-26       Impact factor: 22.113

9.  Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease.

Authors:  K R Cooke; G R Hill; J M Crawford; D Bungard; Y S Brinson; J Delmonte; J L Ferrara
Journal:  J Clin Invest       Date:  1998-11-15       Impact factor: 14.808

10.  Gut microbiota, immunity, and disease: a complex relationship.

Authors:  Michele M Kosiewicz; Arin L Zirnheld; Pascale Alard
Journal:  Front Microbiol       Date:  2011-09-05       Impact factor: 5.640

View more
  16 in total

1.  Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.

Authors:  Jeannine S McCune; Barry Storer; Sushma Thomas; Jožefa McKiernan; Rohan Gupta; Brenda M Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2018-04-12       Impact factor: 5.742

Review 2.  Patient selection for allogeneic hematopoietic cell transplantation (HCT): the evolution of HCT risk assessment.

Authors:  Lori Muffly
Journal:  Curr Hematol Malig Rep       Date:  2015-03       Impact factor: 3.952

Review 3.  Intestinal microbiota-related effects on graft-versus-host disease.

Authors:  Yusuke Shono; Melissa D Docampo; Jonathan U Peled; Suelen M Perobelli; Robert R Jenq
Journal:  Int J Hematol       Date:  2015-03-27       Impact factor: 2.490

4.  Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.

Authors:  Meagan J Bemer; Linda J Risler; Brian R Phillips; Joanne Wang; Barry E Storer; Brenda M Sandmaier; Haichuan Duan; Brianne S Raccor; Michael J Boeckh; Jeannine S McCune
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-09       Impact factor: 5.742

Review 5.  Nonmyeloablative allogeneic hematopoietic cell transplantation.

Authors:  Rainer Storb; Brenda M Sandmaier
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

Review 6.  The gut microbiota and graft-versus-host disease.

Authors:  David N Fredricks
Journal:  J Clin Invest       Date:  2019-05-01       Impact factor: 14.808

7.  Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

Authors:  Mohamed L Sorror; Paul J Martin; Rainer F Storb; Smita Bhatia; Richard T Maziarz; Michael A Pulsipher; Michael B Maris; Christopher Davis; H Joachim Deeg; Stephanie J Lee; David G Maloney; Brenda M Sandmaier; Frederick R Appelbaum; Theodore A Gooley
Journal:  Blood       Date:  2014-05-05       Impact factor: 22.113

8.  Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.

Authors:  Sung Won Choi; Thomas Braun; Lawrence Chang; James L M Ferrara; Attaphol Pawarode; John M Magenau; Guoqing Hou; Jan H Beumer; John E Levine; Steve Goldstein; Daniel R Couriel; Keith Stockerl-Goldstein; Oleg I Krijanovski; Carrie Kitko; Gregory A Yanik; Michael H Lehmann; Isao Tawara; Yaping Sun; Sophie Paczesny; Markus Y Mapara; Charles A Dinarello; John F DiPersio; Pavan Reddy
Journal:  Lancet Oncol       Date:  2013-11-30       Impact factor: 41.316

9.  White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.

Authors:  Haesook T Kim; David Frederick; Philippe Armand; Emily Andler; Grace Kao; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Vincent T Ho
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

10.  Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.

Authors:  Erin Gatza; Thomas Braun; John E Levine; James L M Ferrara; Shuang Zhao; Tianyi Wang; Lawrence Chang; Andrew Harris; Attaphol Pawarode; Carrie Kitko; John M Magenau; Gregory A Yanik; Daniel R Couriel; Steven Goldstein; James Connelly; Pavan Reddy; Sophie Paczesny; Sung Won Choi
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-02       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.